ALS TDI Logo
Sign In
Donate
 Search
2025 Annual Report
Meeting the Moment
ALS research has reached a turning point. New insights into genetics and disease biology, alongside advances in biomarkers and artificial intelligence, are giving researchers more credible therapeutic ideas to pursue than at any point before. However, identifying those ideas is only the beginning. Every potential idea has to be rigorously tested and advanced through the stages of drug discovery. This is the hard but critical work that ALS TDI carries out in our lab every day.
In 2025, we continued that work while building on our capabilities. Several therapeutic programs moved forward, the ALS Research Collaborative (ARC) Study grew, and we opened new collaborations while sharing data and research tools with scientists around the world.
What follows is what that work produced in 2025, and evidence that the capabilities we've built over more than two decades are starting to open doors that weren't there before.
Scroll to explore 2025
Headshot of ALS TDI's CEO/CSO, Dr. Fernando Vieira
A Letter from
Fernando Vieira, M.D.
Chief Executive Officer & Chief Scientific Officer
For many years, one of the greatest challenges in ALS research was a lack of promising therapeutic opportunities.
Today, ALS research has reached a turning point. Advances in genetics, biomarkers, artificial intelligence, and disease biology are generating more promising therapeutic opportunities than ever before. For the first time, scientific opportunity is advancing faster than the systems designed to evaluate it.
That shift demands a new approach.
Discovering a promising therapy is only the beginning. Moving it toward patients requires rigorous testing, reliable biomarkers, relevant disease models, and the ability to make evidence-based decisions at every stage of development.
This is the challenge ALS TDI was built to address.
Throughout 2025, we strengthened the capabilities that make this work possible. We advanced therapeutic programs, expanded the ALS Research Collaborative (ARC), launched Champion Insights to better understand why certain populations face a higher risk of developing ALS, and built new collaborations across academia, industry, and nonprofit organizations. Each of these efforts contributes to the same goal: giving researchers better tools, better data, and stronger evidence to move promising therapies forward.
None of this would be possible without our community. Every participant, donor, volunteer, advocate, and partner has played a role in the progress reflected in these pages.
The work highlighted throughout this report also laid the foundation for an important milestone. In early 2026, ALS TDI announced a landmark expansion of our laboratories and research capabilities. This investment reflects our commitment to meeting this moment— ensuring we have the capacity to evaluate more therapeutic opportunities, advance the strongest ideas with rigor, and help bring effective treatments to people living with ALS faster.
Thank you for your partnership and your belief in what is possible. Together, we are building a stronger future for ALS research.
Fernando Vieira, MD
Chief Executive Officer & Chief Scientific Officer
ALS Therapy Development Institute
At a Glance
2025 At A Glance
In 2025, your support helped ALS TDI make meaningful progress in ALS research. Here's a quick look at our impact and accomplishments throughout the year.
Drug Discovery & Development icon
Drug Discovery & Development
  • Advanced multiple therapeutic programs toward their next stages of development.
  • Deprioritized programs based on data generated internally.
  • Continued development of new mRNA technologies for ALS.
  • Progressed TDI-1831 into IND-enabling studies.
  • Advanced ALS TDI-discovered PRMT inhibitors through preclinical evaluation.
Research Platforms & Biomarkers icon
Research Platforms & Biomarkers
  • Expanded digital biomarker research using voice and movement data.
  • Advanced blood biomarker research to improve how ALS progression is measured.
  • Continued development and validation of disease models for preclinical drug testing.
Research Participation icon
Research Participation
  • More than 1,800 people have now participated in the ALS Research Collaborative (ARC).
  • Participants contributed thousands of voice recordings, movement assessments, blood samples, and functional surveys that continue to support ALS research worldwide.
  • Continued expanding the availability of de-identified research data to investigators through the ARC Data Commons.
Collaboration icon
Collaboration
  • Advanced strategic collaborations across academia, biotechnology, nonprofit organizations, and industry.
  • Continued leadership in initiatives focused on improving digital biomarkers for ALS clinical trials.
  • Contributed expertise, data, and research platforms to collaborative efforts accelerating therapeutic development.
Community Impact icon
Community Impact
  • More than 200 community-led fundraisers supported ALS TDI's mission in 2025.
  • 300+ participated in Ales for ALS, helping fund research while raising awareness across all 50 states.
  • Thousands of riders, runners, volunteers, donors, and advocates came together through events and campaigns to help accelerate the search for treatments.
Discovering and Advancing New Treatments
Every program begins with the same question
A scientist working in ALS TDI's lab in Watertown, MA.
Every program begins with the same question: could this approach lead to a meaningful treatment for people living with ALS?
There is no single cause of ALS, and there won't be a single treatment that works for everyone. That's why ALS TDI is pursuing multiple therapeutic strategies while developing the research tools needed to evaluate them.
Throughout 2025, our researchers advanced new therapeutic approaches while continuing to develop better disease models and biomarkers. Together, these efforts strengthen every stage of the drug discovery process, from identifying promising therapies to evaluating them in preclinical testing and clinical trials.
A scientist working in ALS TDI's lab in Watertown, MA.
Advancing ALS Treatments icon
Advancing Treatments for ALS

Messenger RNA (mRNA) has changed how scientists approach the treatment of many diseases. In 2025, ALS TDI began pioneering this technology for ALS by partnering with Dr. Michael Mitchell at the University of Pennsylvania to develop lipid nanoparticles designed to deliver mRNA-based therapies to the central nervous system. Our scientists also synthesized several mRNA candidates for preclinical testing. Over the next year, we'll be evaluating whether these mRNA candidates can effectively reach and act on key therapeutic targets in ALS.

In 2020, ALS TDI researchers discovered that type I PRMT inhibitors can alter ALS-linked proteins associated with the C9orf72 mutation, the most common genetic cause of ALS. Building on that discovery, our team is now testing PRMT inhibitor compounds in animal models to  determine whether they can correct RNA mis-splicing and reduce protein aggregation—two biological processes believed to contribute to disease progression. Although this work began with C9orf72-related ALS, researchers believe the biology may ultimately have broader applications across other forms of the disease.

Research into copper biology also continued to move forward in 2025. TDI-1831, ALS TDI's most advanced therapeutic candidate, advanced into IND-enabling studies. At the same time, researchers developed patient stratification strategies to help identify the people most likely to benefit from this approach. These studies are generating the data needed to  determine  whether TDI-1831 is ready to move into clinical testing.
Building Better Ways to Test Therapies icon
Building Better Ways to Test Therapies
Discovering a promising therapy is only part of the challenge. Researchers also need reliable ways to evaluate whether that therapy is having the intended effect.
Profilin1 Mouse Model: ALS TDI researchers published the first comprehensive characterization of a Profilin1 mouse model, demonstrating that it closely reflects key features of ALS. This work provides researchers with another well-characterized model for evaluating potential therapies before they move into clinical testing.
Measuring What Matters icon
Measuring What Matters
Biomarkers help researchers measure how ALS progresses and whether an experimental treatment is having its intended effect. Better biomarkers lead to better clinical trials.
Digital Biomarkers:  Researchers continued evaluating how voice recordings and wearable device data collected through the ARC Study correlate with clinical outcomes, bringing these digital biomarkers closer to use in ALS clinical trials. 
Omics:  Analysis of omics data from ARC participants expanded in 2025, helping identify biological signatures associated with disease progression and treatment response.
C9 Biomarkers:  The team also developed new antibodies against methylated C9orf72 dipeptide repeats, research tools that may support future biomarker development and therapeutic research. 
As these tools continue to improve, they have the potential to make clinical trials more informative, more efficient, and better able to identify therapies that truly benefit people living with ALS.
Learning from People with ALS
The Power of Research Participation
An ALS TDI scientist working with research samples.
ALS takes many different forms, and researchers can only make sense of that variation with direct participation from the ALS community. When participants share health information, biological samples, and their experiences with ALS, they give researchers a clearer view of how the disease differs from one person to another and how it changes over time.
In 2025, ALS TDI's partnership with the ALS community continued through the growth of the ALS Research Collaborative (ARC) Study and the announcement of Champion Insights.
An ALS TDI scientist working with research samples.
The ALS Research Collaborative (ARC)
The ALS Research Collaborative (ARC) is the longest-running natural history study in ALS and one of the largest efforts to collect real-world data from people living with the disease.
Through ARC, participants contribute health records, survey responses, voice recordings, wearable device data, and blood samples.
Each data type helps researchers better understand how ALS develops and progresses. Those data are shared through the ARC Data Commons, where researchers around the world can use them to ask new questions, test new ideas, and build on one another's work.
ARC By The Numbers
8.5T+
data points collected
50 / 49
countries and U.S. states represented
8
scientific publications supported
100+
research institutions accessing data through the ARC Data Commons
#1
One of the world's largest repositories for ALS digital biomarker research
Behind those numbers are thousands of people who have contributed their data to move ALS research forward. Here are a few ways researchers are putting ARC data to work today.

Together with Axol Bioscience, ALS TDI is developing stem cell models that better reflect the diversity of ALS, with an emphasis on development of sporadic ALS models. Many of these models are created using samples donated by ARC participants, giving researchers more representative tools for studying the disease and evaluating potential therapies.

ARC data is also supporting the Longitude Prize on ALS, a global initiative that uses artificial intelligence to uncover patterns hidden within large research datasets. By combining ARC data with other sources, researchers hope to identify new clues about how ALS develops and where new treatment opportunities may exist.

ARC data is being added to the Answer ALS Neuromine platform, where researchers will be able to access and explore it alongside other major ALS datasets. Bringing these data together will make it easier for scientists to compare findings, investigate new research questions, and work across institutions.
Champion Insights icon
Champion Insights: Understanding Risk to Find New Answers
Military veterans, elite athletes, and first responders seem to be diagnosed with ALS at higher rates than the general population. Champion Insights was created to investigate why.
Announced in 2025 by ALS TDI, Answer ALS, and Augie's Quest to Cure ALS, the study will investigate the genetic, biological, clinical, environmental, and lifestyle factors that may contribute to the increased risk of ALS in these populations.
Champion Insights builds on the foundation of the ARC Study. By comparing data from these higher-risk groups with the broader ARC population, researchers will be able to identify patterns, evaluate potential biomarkers, and better understand the biological pathways that may contribute to ALS.
The insights gained from this work could lead to new approaches for understanding, diagnosing, and ultimately treating the disease.
ALS Research Collaborative icon
Research Powered by Participation
ARC now includes contributions from thousands of participants across 50 countries. Champion Insights adds a new, targeted layer to that dataset — and each new participant sharpens what both studies can reveal.
As these data sets continue to grow, so does our ability to advance more effective treatments for ALS.
ALS Research Partnerships
Driving Progress Through Collaboration
An ALS TDI scientists performing experiments in the lab.
No single organization has the resources to identify, test, and validate every promising approach to treating ALS. Progress requires researchers, nonprofits, and industry partners to share data and expertise — and it requires an organization positioned to carry promising discoveries from the lab toward the clinic.
That is the role ALS TDI was built to play.
ALS TDI has built the scientific team, research platforms, and infrastructure to do that work. Our team evaluates therapeutic approaches from outside labs and industry partners against our own data and models to determine which have the greatest potential to advance. In 2025, several collaborations strengthened this work.
An ALS TDI scientists performing experiments in the lab.
2025 Collaboration Highlights

ALS TDI partnered with Axol Bioscience to develop and distribute stem cell models derived from people living with sporadic ALS. Because they're built from samples donated by ARC participants, these models capture genetic and clinical diversity that most existing ALS models lack. This work was an integral part of the PRISM initiative, which was announced in 2026 to expand access to high-quality stem cell models that better reflect the biological complexity of ALS.

Together with Answer ALS and Augie’s Quest, ALS TDI announced the launch of Champion Insights, a first-of-its-kind research initiative focused on understanding why military veterans, first responders, and elite athletes appear to face a higher risk of developing ALS. Built on the ARC platform, the study will generate new data that could reveal important clues about disease risk and biology.

Working with LifeArc, ALS TDI is identifying and validating blood-based biomarkers that could improve how ALS is diagnosed and monitored. Using samples collected through the ARC Study, researchers have already identified promising markers that may help predict how quickly the disease progresses—an important step toward improving clinical trials and evaluating future therapies.

Through a collaboration with the Critical Path Institute (C-Path), ALS TDI is evaluating wearable device data from the ARC Study to identify potential new ways to measure disease progression in ALS clinical trials. These digital biomarkers could help make future trials more sensitive and better able to detect whether a potential treatment is having a meaningful impact.

The Longitude Prize on ALS, organized by Challenge Works, challenges researchers around the world to develop AI-powered tools that accelerate ALS research. As a data partner, ALS TDI is contributing more than a decade of patient data from the ARC Study. We’re also collaborating with researchers at Google to explore how artificial intelligence can uncover patterns that may lead to new insights into ALS.
Advancing Research Together
These collaborations reflect the different roles ALS TDI plays within the ALS research ecosystem. Whether we're providing data, developing models, validating discoveries, or evaluating new therapies, the goal is to move the most promising ideas forward.
ALS won't be solved by one lab or one breakthrough. But by bringing together the right people, tools, and evidence, we can move faster toward treatments that work.
Open Science and Data Sharing
Sharing Findings to Inform Global Research
Dr. Fernando Vieira speaking at the 2025 ALS TDI Summit.
At ALS TDI, we believe that sharing findings with the global research community is essential to advance our collective understanding of ALS. In 2025, ALS TDI researchers published papers, presented posters, and spoke at conferences across the country, including our own ALS TDI Summit in Boston.
Dr. Fernando Vieira speaking at the 2025 ALS TDI Summit.
2025 ALS TDI Summit
At the 2025 ALS TDI Summit, our researchers and collaborators presented the year's work — from new technologies to shared datasets to the partnerships described above — and discussed how this shapes where ALS drug discovery goes next. The day's agenda included:
Updates from ALS TDI researchers on our progress in 2025: 
  • CEO and CSO Dr. Fernando Vieira on ALS TDI's efforts to advance a portfolio of diverse therapeutic approaches for ALS. 
  • ALS TDI Director of Clinical Operations Alan Premasiri on the continued impact of the ARC Study, which now includes data provided by more than 1,800 people with ALS. 
  • Director of Data Science Dr. Danielle Boyce on our efforts to create actionable insights from big data, including electronic health records and self-reported data from the ARC Study. 
Panel Discussion:
A panel discussion on the value of collaboration and data sharing in ALS research, moderated by Dr. Danielle Boyce and featuring industry leaders including: 
  • Fernando Vieira, M.D., CEO/CSO, ALS TDI  
  • Tonya Gilbert, Ph.D., Executive Director of Translational Research, Eikonizo 
  • Irina Antonijevic, M.D., Ph.D., Chief Medical Officer, Trace Neuroscience 
  • Tris Dyson, Founder and Managing Director, Challenge Works 
Guest Presentations:
Presentations from ALS TDI's collaborators:
  • Dr. Amalia Papanikolaou and Tris Dyson of Challenge Works on the Longitude Prize for ALS, a global competition using artificial intelligence to identify new therapeutic targets for ALS utilizing data from sources including ALS TDI’s ARC Study. 
  • Dr. Rebeca James of Eikonzio Therapeutics on HDAC6, a potential new drug target for ALS, currently undergoing preclinical validation in collaboration with ALS TDI. 
  • Dr. Michael Mitchell of the University of Pennsylvania on his collaboration with ALS TDI to develop lipid nanoparticles (LNPs) to deliver mRNA therapeutics for ALS to the brain and spinal cord. 
View the full 2025 ALS TDI Summit recap here
2025 Peer Reviewed Publications
Peer review means other scientists, with no stake in our results, examined this work before it reached print. That outside scrutiny is an important part of scientific discovery. it's the difference between a claim and a claim other labs are willing to build on.
  1. James, R.E., Bekier, M., Lee, P.-T.J., Schroeder, F.A., Evans, L.T., Wagner, F.F., Hickman, D., Richardson, T., Hatzipetros, T., Vieira, F., Callizot, N., Modi, S., Hooker, J.M., Kranz, J.E., Brown, R.H. Jr., Barmada, S.J., Gilbert, T.M.. A next-generation HDAC6 inhibitor for amyotrophic lateral sclerosis and frontotemporal dementia. Brain. (2025).
  2. Mueller, K.A., Suneby, E.G., Ferola, M.H., Moreno, A.J., Kidd, J.D., Thompson, K., Vieira, F.G., Valdez, G., Hatzipetros, T. Comprehensive characterization and validation of the Prp-hPFN1G118V mouse model: Guidelines for preclinical therapeutic testing for ALS. Neurobiology of Disease. 212 (2025).
  3. Straczkiewicz, M., Burke, K.M., Carney, K.T., Calcagno, N., Mandepudi, S., Premasiri, A., Vieira, F.G., Berry, J.D. Analytical and clinical validation of step counting method in people living with amyotrophic lateral sclerosis. Scientific Reports. (2025).
  4. Imam, F., Saloner, R., Vogel, J.W., Krish, V., Abdel-Azim, G., Ali, M., An, L., Anastasi, F., Bennett, D., Pichet Binette, A., Boxer, A.L., Bringmann, M., Burns, J.M., Cruchaga, C., Dage, J.L., Farinas, A., Ferrucci, L., Finney, C.A., Frasier, M., Hansson, O., Hohman, T.J., Johnson, E.C.B., Kivimaki, M., Korologou-Linden, R., Ruiz Laza, A., Levey, A.I., Liepelt-Scarfone, I., Lu, L., Mattsson-Carlgren, N., Middleton, L.T., Nho, K., Oh, H.S.-H., Petersen, R.C., Reiman, E.M., Robinson, O., Rothstein, J.D., Saykin, A.J., Shvetcov, A., Slawson, C., Smets, B., Suárez-Calvet, M., Tijms, B.M., Timmers, M., Vieira, F., Vilor-Tejedor, N., Visser, P.J., Walker, K.A., Winchester, L.M., Wyss-Coray, T., Yang, C., Bose, N., Lovestone, S.; Global Neurodegeneration Proteomics Consortium (GNPC). The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nature Medicine. (2025).
2025 Selected Posters, Talks, and Panels
A poster session puts unfinished work in front of other researchers that are equipped to review and challenge it. The questions that come out of a hallway conversation at a conference, or a pointed comment after a talk, can be critical to shaping the final project.
  • Dr. Fernando Vieira, CEO and Chief Scientific Officer. ALS TDI Takeaway in Large Scale Actigraphy Research, keynote address at the ActiGraph Digital Data Summit 2025.
  • Dr. Fernando Vieira, Uniting Forces: Collaborative Initiatives Driving ALS Drug Development Through Data Sharing & Accelerated Research, Panel Discussion, 4th Annual ALS Drug Development Summit.
  • Dr. Theo Hatzipetros, Senior Director of Pharmacology, Pharmacological Inhibition of Traf2- and Nck-Interacting Kinase (TNIK) as a Treatment for ALS, poster presentation at the ALS TDI Summit.
  • Valerie Tassinari. Associate Scientist III, Zebrafish Program Manager: Visualizing C9orf72 DPR Localization using Larval Zebrafish Whole-Mount Immunofluorescence, poster presentation at the ALS TDI Summit.
  • Josh Berman, Associate Scientist III, ALS Research Collaborative: Overview of A Participant-Driven, Longitudinal Study to Capture and Quantify Trends in Disease Presentation and Progression, poster presentation at the ALS TDI Summit.
  • Dr. Kyle Denton, Senior Director of Cell Biology, Generation of human induced pluripotent stem cell based TDP-43 knockout in vitro model for disease modeling, poster presentation at the ALS TDI Summit.
  • Amit Mishra, Integrating Robotics and Automated Image Analysis to Optimize Neuronal Spot Cultures and Lysosome Transport Assays, poster presentation at the ALS TDI Summit.
  • Dr. Danielle Boyce, Director of Data Science, Research-Ready Electronic Health Records: A Reproducible Pipeline for the ARC Natural History Study, poster presentation at the International Symposium on ALS/MND.
  • Kaly Mueller, Targeting Type I PRMTs in ALS: In Vivo Evaluation of MS023 and GSK3368715 in TDP43Q331K and SOD1G93A Mice, poster presentation at the International Symposium on ALS/MND.
  • Swetha Gurumurthy, Associate Scientist II: A Robust Workflow for Cryopreservation of iPSC-Derived Motor Neurons and Optimized Expansion of Motor Neuron Progenitors for Disease Modeling, poster presentation at the International Symposium on ALS/MND.
Fundraising and Awareness
Community Impact
As a nonprofit biotech, ALS TDI depends on our community to fund and drive every research breakthrough. In 2025, more than 200 individuals organized fundraisers for ALS drug discovery, joined by thousands of supporters who donated, volunteered, and spread the word.
Here are just a few of the inspiring ways our community came together to support our mission.
Attendees at Brewing a Cure Goes Golfing.
Brewing a Cure Goes Golfing
~$300,000 raised in 2025
In May of 2018, Dennis Ceruti—a hardworking, healthy living, loving husband and father of four amazing girls—was diagnosed with ALS. The next year, his friends and family organized Brewing a Cure for ALS, a beer festival that raised nearly $150,000 for ALS TDI.
Sadly, Dennis passed in May of 2020 after a 2-year battle with ALS. It was always his goal to raise money to find a cure, to ensure no one else, or their families had to endure the pain that is ALS. In 2024, led by two of Dennis’s best friends, Camille and Dave, friends and family of Dennis came together and re-lauched Brewing a Cure for ALS as a golf outing. In 2025, year two of Brewing a Cure Goes Golfing, nearly $300,000 has been raised in honor of Dennis for research at ALS TDI.
Brewing a Cure for ALS lives on in his memory to finish what Dennis started.
Presentation of a check from the Hummingbird Fund.
The Hummingbird Fund
$100,000+ over 2 years
The Hummingbird Fund was founded by Drs. Jim and Peggy Plews-Ogan along with their family and friends. It serves as an accelerator for innovation in ALS research, advocacy, and overall functional support, through stable and sustainable partnerships that are family- and patient-centric. Sadly, Jim passed away on July 3, 2024, but the work of the Hummingbird Fund continues, in Jim’s honor and memory.
Following their mission to support patient-centric research, The Hummingbird Fund has generously donated over $100,000 (over 2 years), to support the work at ALS TDI, specifically our ARC study. Their support has helped us to increase enrollment in the ALS Research Collaborative (ARC) Study, with a focus on enrolling young women who have been diagnosed with ALS.
Attendees at the Dance Away ALS event.
Dance Away ALS
$56,000 in 2025
Dance Away ALS is an annual evening of music, dancing, and raffles held at Noble Funk Brewing Company in Louisville, Kentucky. It is organized by Katie Rixman, who lost her sister, Susanna Dennis, to the disease.
In 2025, the event honored Katie's friends living with ALS today, Stephan Korner and Aimee Smith, as well as those she has lost to the disease, including her Susanna, Bill Cunningham, Terry Hunt, Laura McDonald, Lyle Hawkins, Hal Burgiss, Tonya Anderson, Randy Puno, and many more. Over three years, the event has raised more than $145,000 for ALS research at ALS TDI, including $56,000 in 2025.
Timm Fenton posing with his bike while cycling across the country to raise money for ALS TDI.
Pedals vs. ALS
$50,000+ raised
On May 1, 2025, Timm Fenton started riding his bike east from the Pacific Coast in Florence, Oregon. 67 days later he arrived at the Atlantic Ocean in Yorktown, Virginia.
Timm's effort, which he named "Pedals vs. ALS," was inspired by his mother, Jan, who he lost to ALS in 2017. Along his more than 4200-mile route, he crossed snow- covered mountains, faced intense storms through the Great Plains, and was even chased by wild dogs on remote country backroads. Timm shared the stories of his triumphs and challenges, as well as spreading ALS awareness, throughout his journey, ultimately raising more the $50,000 for ALS research at ALS TDI.
Meeting the Moment
Expanding the Capacity to End ALS
Across ALS research, there are now more promising leads than the field has the capacity to test.
ALS TDI announced a landmark expansion of its lab and research team, beginning in 2026. This investment will allow us to evaluate more therapies, develop more advanced disease models, strengthen biomarker discovery, and move the most promising programs forward more efficiently.
Made possible through the generosity of our donor community and a transformational commitment from Augie's Quest to Cure ALS, this expansion is an investment in the future of ALS research.
33,000 sq. ft.
New research facility
2x Science Team
Doubling our scientific workforce
Expanded Capacity
Evaluate more therapeutic opportunities in parallel
New Technologies
Advance biomarker discovery and drug testing
Powered by Community
Made possible through donor support
Augie's Quest to Cure ALS: A Commitment Built Over Time
Augie's Quest to Cure ALS has supported ALS TDI for nearly two decades. Over the years, that partnership helped ALS TDI strengthen its research capabilities and build the foundation for this next stage of growth.
Today, a transformational commitment from Augie's Quest to Cure ALS is helping make ALS TDI's landmark expansion possible.
This commitment carries forward the vision of Augie Nieto, co-founder of Augie's Quest to Cure ALS and longtime chair of ALS TDI's Board of Directors. Augie understood that ending ALS would require research conducted with urgency, ambition, and the flexibility to follow the science wherever it leads.
Although Augie passed away in 2023, his mission and legacy continue. We are deeply grateful for his leadership and for the continued commitment of Augie's Quest to Cure ALS to ALS TDI's research.
Financial Overview
2025 Financials
A look at ALS TDI's revenue, expenses, and financial position over the past five fiscal years, drawn directly from the underlying financial statements.
$16.4M
Total 2025 revenue
$13.1M
Total 2025 expenses
90.5%*
Of 2025 expenses to program services
$19.3M
Net assets, up from $16.5M in 2021
Where the money came from
Net public support and revenue by source, FY2025. Hover or tap any segment for detail.
Where the money went
Operating expenses by function, FY2025. Purple tones are program services; navy and blue are support services.
Five-year trend
Total revenue, total expenses, and year-end net assets by fiscal year, FY2021–FY2025.
Advancing Research Together
Looking Ahead
ALS TDI's expansion represents a pivotal moment not only for our organization, but for ALS research as a whole. It reflects the level of commitment, investment, and scientific rigor that people with ALS need and deserve. We are proud and deeply grateful to take this next step alongside you.
Our capacity to test drugs and advance treatments will continue to grow alongside the pace of discovery. With your support, we will move this work forward with urgency while continuing to serve as a hub for collaborative ALS research.
Expanding Our Research Capacity
Following the announcement of our expansion, we will begin growing our science team and begin construction on a new research facility in Watertown, MA. By doubling the size of our lab and our team, we'll be able to explore more ideas and test more promising drugs in parallel.
Expanding Research Participation and Data Resources
The ALS Research Collaborative (ARC) Study will continue to grow as one of the world's most comprehensive ALS natural history studies. At the same time, Champion Insights will begin enrolling military veterans, elite athletes, and first responders, with the goal of uncovering factors that may contribute to higher risk of ALS in these populations.
Advancing Therapeutic Discovery
Our researchers will continue advancing multiple therapeutic programs, including mRNA technologies, TDI-1831, and PRMT inhibitors. At the same time, we will continue to pursue new therapeutic opportunities emerging from discoveries in our own lab and from collaborations across the ALS community.
Building Better Tools for Drug Discovery
ALS TDI will continue expanding the tools researchers need to develop better therapies. That includes launching PRISM ALS to increase access to sporadic models of ALS, advancing digital and blood-based biomarkers, and improving the technologies that help researchers evaluate potential treatments.
An ALS TDI scientist performing experiments at a lab bench.
Thank You
Thank You for Making This Progress in ALS Research Possible
As we look ahead, we believe this turning point marks the beginning of a new era in ALS research. We will continue moving this work forward with urgency while serving as a hub for collaboration across the ALS research community.
Your support gives us the freedom to pursue the most promising science wherever it leads. Together, we are building the pipeline for the next generation of ALS treatments.